Get the Stockscreener App
3.62
3.13%
0.11
After Hours:
3.62
Climb Bio Inc stock is traded at $3.62, with a volume of 396.27K.
It is up +3.13% in the last 24 hours and up +0.00% over the past month.
Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. its lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has the potential to treat a broad range of B-cell-mediated diseases.
See More
Previous Close:
$3.51
Open:
$3.49
24h Volume:
396.27K
Relative Volume:
3.64
Market Cap:
$242.76M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-10.40%
1M Performance:
+0.00%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$3.41
$3.83
1-Week Range:
$3.41
$4.12
52-Week Range:
$3.41
$5.47
Climb Bio Inc Stock (CLYM) Company Profile
Name
Climb Bio Inc
Sector
Industry
Phone
877-354-3689
Address
2801 CENTERVILLE ROAD 1ST FLOOR, WILMINGTON
Climb Bio Inc Stock (CLYM) Latest News
Climb Bio to Present at Upcoming Investor Conferences - GlobeNewswire
Nasdaq Futures Climb on Upbeat Alphabet Results, U.S. GDP Data and More Big Tech Earnings on Tap - MSN
Humic Acid Market Set to Climb to USD 1.63 Billion by 2030 - openPR
ABVC BioPharma receives $50,000 in incremental licensing fees, shares climb - MSN
Tevogen Bio (TVGN) Sees Major Stock Surge After Key AI Move - Stocks Telegraph
Interpublic Group Of Cos., Inc. (IPG): Worth A Small Bite At $32.03 - Stocks Register
Why Lamb Weston Stock Was Climbing Today - Yahoo Finance
Big Bank Stocks Climb. 3 Stocks to Consider Adding to Your Portfolio. - Yahoo Finance
Merck & Co’s Clesrovimab Has Beyfortus Hill To Climb In RSV - Citeline
Treasury Yields Climb as Strong Data Sow Doubt on Fed Rate Cuts - Yahoo Finance
Mortgage Demand Sees Sharpest Weekly Drop Since April 2020 As Rates Climb Above 6.5% - Yahoo Finance
Korean growth stocks climb after rate cut - 코리아타임스
Vale Achieves Six-Year High in Iron Ore Output, Copper and Nickel Production Also Climb - Yahoo Finance
European Wax Center Continues to Climb in Franchise Times' Top 400 Ranking - Yahoo Finance
US Mortgage Rates Climb to 6.52%, Highest Since Early August - Yahoo Finance
What You Need to Know Ahead of Bio-Techne's Earnings Release - TradingView
Stocks of B. Riley Financial Inc (RILY) are poised to climb above their peers - SETE News
Climb Bio to Provide Budoprutug Development Strategy and Corporate Update at Virtual Investor Event - The Manila Times
‘Retirement super pot’ holders pay themselves around £3m each in a year - Yahoo Finance UK
Climb Bio to present kidney disease treatment study By Investing.com - Investing.com Australia
Climb Bio Announces Abstract Selected for Presentation at the American Society of Nephrology Kidney Week 2024 - GlobeNewswire
Climb Bio to present kidney disease treatment study - Investing.com India
Climb Bio Announces Abstract Selected for Presentation at the American Society of Nephrology - The Bakersfield Californian
A stock that deserves closer examination: Climb Bio Inc. (CLYM) - US Post News
Climb Global (CLMB) Surged on Strong Results - Yahoo Finance
Quarterly IPOs Climb Back Above $1bn - Scrip
US 30-Year Mortgage Rate Climbs by Most in More Than a Year - Yahoo Finance
Climb Global (CLMB) Moves 7.0% Higher: Will This Strength Last? - Yahoo Finance
FDA Oncology Approvals Accelerate as Global Cancer Rates Set to Climb 77% - Baystreet.ca
Climb Bio to Present at William Blair’s Upcoming Conference Event on Transforming Autoimmune Diseases by Targeting CD19 - ForexTV.com
Climb Bio to Present at William Blair’s Upcoming Conference - GlobeNewswire
Climb Bio to Present at William Blair's Upcoming Conference Event on Transforming Autoimmune Diseases by Targeting CD19 - The Manila Times
Intumescent Coatings Market Size to Climb to USD 2.4 - GlobeNewswire
Intumescent Coatings Market Size to Climb to USD 2.4 billion by 2034 with a 7.4% CAGR, Supported by Steel Fabrication Fireproofing Demand | States Transparency Market Research, Inc. - Yahoo Finance
First Merchants Corporation to Report Third Quarter 2024 Financial Results, Host Conference Call and Webcast - The Manila Times
Climb Bio to Host Virtual Investor Event on October 15, 2024 - GlobeNewswire
Eliem Therapeutics rebrands to Climb Bio, shifts focus to immune diseases By Investing.com - Investing.com South Africa
Eliem Therapeutics rebrands to Climb Bio, shifts focus to immune diseases - Investing.com
Eliem Therapeutics Changes Name to Climb Bio - Yahoo Finance
Eliem Therapeutics to change corporate name to Climb Bio - TipRanks
Techmer PM Expands Portfolio with Acquisition of OptiColor Inc. - The Manila Times
Eliem Therapeutics Announces Rebranding and Corporate Name Change to Climb Bio, Inc. - The Bakersfield Californian
Cisco Set For Technical Breakout As Golden Cross Signals Strength: Analyst Predicts Stock Will 'Quietly' Climb Higher - Yahoo Finance
Sino Biological,Inc.'s (SZSE:301047) Shares Climb 31% But Its Business Is Yet to Catch Up - Simply Wall St
Home sales climb with lower mortgage rates - Yahoo Finance
China’s Biggest Stock Buying Frenzy in Years Overwhelms Exchange - Yahoo Finance
Biomea stock jumps 9% after FDA lifts hold on Phase 1/2 study (update) - MSN
Nvidia Corp (NVDA-Q) QuotePress Release - The Globe and Mail
The price of gold keeps climbing to unprecedented heights. Here's why - Yahoo Finance
Equities, commodities climb after China announces stimulus - Yahoo Finance
Eliem Therapeutics: Recent Strategic Pipeline Restructuring (NASDAQ:ELYM) - Seeking Alpha
Climb Bio Inc Stock (CLYM) Financials Data
There is no financial data for Climb Bio Inc (CLYM). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
Climb Bio Inc Stock (CLYM) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Morisset Valerie | EVP, R&D AND CSO |
Jul 22 '24 |
Sale |
8.03 |
69,005 |
554,170 |
31,317 |
| Morisset Valerie | EVP, R&D AND CSO |
Jul 19 '24 |
Sale |
7.21 |
60,201 |
434,325 |
100,322 |
| Morisset Valerie | EVP, R&D AND CSO |
Jul 18 '24 |
Sale |
6.93 |
38,576 |
267,332 |
160,523 |
| Morisset Valerie | EVP, R&D AND CSO |
Jul 17 '24 |
Sale |
6.91 |
3,207 |
22,160 |
199,099 |
| Morisset Valerie | EVP, R&D AND CSO |
Jul 16 '24 |
Sale |
7.13 |
50,000 |
356,500 |
202,306 |
| Morisset Valerie | EVP, R&D AND CSO |
Jul 12 '24 |
Sale |
7.07 |
50,000 |
353,500 |
294,683 |
| Morisset Valerie | EVP, R&D AND CSO |
Jul 15 '24 |
Sale |
7.01 |
42,377 |
297,063 |
252,306 |
| Morisset Valerie | EVP, R&D AND CSO |
Jul 11 '24 |
Sale |
7.11 |
50,000 |
355,500 |
344,683 |
| Morisset Valerie | EVP, R&D AND CSO |
Jul 10 '24 |
Sale |
6.83 |
50,000 |
341,500 |
394,683 |
| Morisset Valerie | EVP, R&D AND CSO |
Jul 09 '24 |
Sale |
6.66 |
5,931 |
39,500 |
444,683 |
2.02%
0.47%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):